Clinical Trials
2 trialsNCT03762122 2022-11-09
Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
Swiss Cancer Institute
Phase 2 Terminated
NCT04040725 2019-12-17
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Dana-Farber Cancer Institute
Phase 2 Withdrawn